Edwards Lifesciences Corporation (NYSE: EW) Securities Fraud Class Action

Case Background:
This is a federal securities fraud class action lawsuit on behalf of those who purchased or otherwise acquired Edward Lifesciences Corporation (“Edwards”) (NYSE: EW) common stock between February 6, 2024 and July 24, 2024, inclusive (the “Class Period”).

Edwards is a medical technology company that develops, manufactures, and markets devices for structural heart disease, critical care, and surgical monitoring. Edwards’ primary product is the Transcatheter Aortic Valve Replacement (“TAVR”), which is a minimally invasive alternative procedure to open-heart surgery in certain circumstances.

The Class Period begins on February 6, 2024, when Edwards issued its fourth quarter results. In connection with its results, the company published a press release, highlighting, in pertinent part, the significant progress that was made by the TAVR – stating that “Q4 TAVR sales grew 13 percent; constant currency sales grew 12 percent.”

The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company’s business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) TAVR volume had started declining as early as 2023; (2) TAVR sales growth was limited at least in part due to hospital capacity constraints; (3) hospitals were dedicating their limited resources to more time and cost efficient procedures other than the TAVR; and (4) as a result of the foregoing, Defendants’ statements about the company’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.

Current Status of Case:
On October 21, 2025, Defendants filed an Answer to the Amended Complaint. This action is in the discovery phase and is ongoing.

If you wish to discuss this action or have any questions, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at [email protected]. If you would like additional information about the suit, please click on the link “Submit Your Information” above and fill out the form as promptly as possible.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including The National Law Journal’s Plaintiff’s Hot List and Trailblazers in Plaintiffs’ Law, BTI Consulting Group’s Honor Roll of Most Feared Law Firms, The Legal Intelligencer’s Class Action Firm of the Year, Lawdragon’s Leading Plaintiff Financial Lawyers, and Law360’s Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent.